Related Experiment Video
Updated: Feb 15, 2026
Author Spotlight: Developing Photo-Stimulation Technology for Toxin Removal in Sleep-Related Brain Diseases
Published on: June 28, 2024
Onabotulinum toxin-A injections for sleep bruxism: A double-blind, placebo-controlled study
William G Ondo1, Jerald H Simmons2, Muhammad H Shahid2
1From the Department of Neurology (W.G.O., M.H.S., V.H.), Methodist Neurological Institute, Houston, TX; Department of Neurology (W.G.O.), Weill Cornell Medical School, New York, NY; Parkinson's Disease Center and Movement Disorders Clinic (C.H., J.J.), Department of Neurology, Baylor College of Medicine; and Comprehensive Sleep Medicine Associates (J.H.S.), Sleep Title Education Consortium, Houston, TX. wondo@houstonmethodist.org.
Objectives:
To test the safety and efficacy of onabotulinum toxin-A (BoNT-A) injections into the masseter and temporalis muscles in patients with symptomatic sleep bruxism.
Methods:
Participants 18 to 85 years old with clinically diagnosed sleep bruxism confirmed by polysomnography were enrolled in this randomized, placebo-controlled, 1:1, parallel-design trial with open-label extension. Participants were injected with BoNT-A 200 units (60 into each masseter and 40 into each temporalis) or placebo and were evaluated at 4 to 8 weeks after the initial treatment visit. The primary efficacy endpoint was clinical global impression (CGI), and the secondary efficacy endpoint was a visual analog scale (VAS) of change in bruxism and in pain at 4 to 8 weeks after injection. Exploratory endpoints included modified Montreal Bruxism Questionnaire, Headache Impact Test-6, total Pittsburgh Sleep Quality Index, Epworth Sleepiness Scale, Self-Rated Anxiety Scale, and polysomnography data, including EMG recordings of the masseter and temporalis muscle bruxing events. Adverse events were recorded.
Results:
Thirty-one participants were recruited and 23 were randomized (19 female, age 47.4 ± 16.9 years). All 13 randomized to BoNT-A and 9 of 10 randomized to placebo completed the study. CGI (p < 0.05) and VAS of change (p < 0.05) favored the BoNT-A group. None of the exploratory endpoints changed significantly, but total sleep time and number/duration of bruxing episodes favored the BoNT-A group. Two participants randomized to BoNT-A reported a cosmetic change in their smile. No dysphagia or masticatory adverse events were reported.
Conclusions:
BoNT-A effectively and safely improved sleep bruxism in this placebo-controlled pilot trial. A large multicenter trial is needed to confirm these encouraging data.
Clinicaltrialsgov Identifier:
NTC00908050.
Class Of Evidence:
This study provides Class II evidence that botulinum injections into the masseter and temporalis muscles improve subjective bruxism and painful symptoms associated with sleep bruxism.
Related Concept Videos
02:07Blind Procedures
01:54The Placebo Effect
01:11Blinding
01:13Insufficient Sleep and Sleep Deprivation
Sleep deprivation is a more severe form of sleep loss...
01:36Types of Toxins
Air pollutants, primarily gases, pose significant threats to respiratory health, leading to conditions like hypoxia, lung cancer, and in extreme cases, death.
Environmental pollutants like...
01:23Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...